Information Provided By:
Fly News Breaks for November 26, 2019
ARWR
Nov 26, 2019 | 06:20 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $72 from $54 and reiterates an Overweight rating on the shares following last night's results. The company expects to have three pivotal Phase III trials underway in 2020, Tenthoff tells investors in a research note. He believes Arrowhead's RNAi will address both orphan and broader cardiovascular indications characterized by high triglycerides.
News For ARWR From the Last 2 Days
There are no results for your query ARWR